Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Metastasis is the primary cause of death in prostate cancer.
• TP53 mutations are implicated in cancer progression, but their specific role in prostate cancer metastasis is unclear.
• Identifying novel therapeutic targets for metastatic prostate cancer is a critical clinical need.

Purpose of the Study:

• To investigate the role of TP53 mutations in prostate cancer metastasis.
• To elucidate the underlying molecular mechanisms involving TP53 and its downstream targets.
• To explore potential therapeutic strategies targeting TP53 and FOXA1 in prostate cancer.

Main Methods:

• Bioinformatics analysis of TP53 mutation status in prostate cancer datasets.
• Correlation analysis of TP53 mutation site rs12947788 with clinical parameters (metastasis, TNM stage, Gleason score).
• Assessment of forkhead box A1 (FOXA1) expression in prostate cancer tissues and cell lines.
• In vitro functional assays involving FOXA1 knockdown to evaluate cell migration.

Main Results:

• TP53 is the most frequently mutated gene in prostate cancer, with missense mutations being predominant.
• The TP53 rs12947788 mutation site is significantly associated with prostate cancer metastasis and advanced TNM stage.
• FOXA1, a TP53 target, shows high expression in prostate cancer, particularly in TP53-mutant cases, and correlates with Gleason score and nodal metastasis.
• Downregulation of FOXA1 inhibits prostate cancer cell migration in vitro.

Conclusions:

• TP53 mutations, specifically rs12947788, play a significant role in prostate cancer metastasis.
• The TP53-FOXA1 axis is a key pathway involved in prostate cancer progression and metastasis.
• Targeting TP53 mutations and FOXA1 represents a promising therapeutic avenue for managing metastatic prostate cancer.